TLR9 and hepatocellular carcinoma: 3A and 3B). Drp1-mediated CCL2 secretion was also significantly inhibited by treatment with ODN INH-18, PDTC (Fig. 4f), or siRNA for p65 and TLR9 (Supplementary Figure. 3C and 3D). In addition, HCC patients with high TLR9 expression had a significantly poorer overall survival (log rank p < 0.01) and recurrence-free survival (log rank p < 0.01) than those with low TLR9 expression (Supplementary Figure. 4A and 4B).